CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionD. E. Shaw & Co., Inc.
ManagerDE Shaw
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
D. E. Shaw & Co., Inc. ownership in CRSP / CRISPR Therapeutics AG

On February 14, 2025 - D. E. Shaw & Co., Inc. filed a 13F-HR form disclosing ownership of 0 shares of CRISPR Therapeutics AG (US:CRSP) valued at $0 USD as of December 31, 2024. The entity filed a previous 13F-HR on November 14, 2024 disclosing 29,365 shares of CRISPR Therapeutics AG. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

D. E. Shaw & Co., Inc. has a history of taking positions in derivatives of the underlying security (CRSP) in the form of stock options. The firm currently holds call options representing 142,700 of underlying shares valued at $6,788,239 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

CRSP / CRISPR Therapeutics AG Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -29,365 -100.00 0 -100.00
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 29,365 1,191 4.23 1,380 -9.34 0.0012
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 28,174 -146,121 -83.84 1,522 -87.20 0.0014
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 174,295 137,023 367.63 11,880 409.17 0.0102
2024-02-14 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 37,272 37,272 2,333 0.0020
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -4,600 -100.00 0 -100.00
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 4,600 -9,300 -66.91 208 -63.19 0.0002
2023-02-14 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 13,900 13,900 565 0.0006
2022-08-15 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 0 -37,620 -100.00 0 -100.00
2022-05-16 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 37,620 14,448 62.35 2,361 34.45 0.0022
2022-02-14 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 23,172 -11,524 -33.21 1,756 -54.79 0.0015
2021-11-15 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 34,696 9,798 39.35 3,884 -3.65 0.0035
2021-08-16 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 24,898 -52,294 -67.75 4,031 -57.14 0.0035
2021-05-17 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 77,192 -205,959 -72.74 9,406 -78.30 0.0091
2021-02-16 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 283,151 16,284 6.10 43,353 94.23 0.0388
2020-11-16 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 266,867 -61,757 -18.79 22,321 -7.57 0.0228
2020-08-14 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 328,624 52,765 19.13 24,150 106.41 0.0288
2020-05-15 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 275,859 267,192 3,082.87 11,700 2,115.91 0.0183
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 8,667 -11,417 -56.85 528 -35.84 0.0006
2019-11-14 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 20,084 13,065 186.14 823 148.64 0.0010
2019-08-14 2019-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 7,019 467 7.13 331 41.45 0.0004
2019-05-15 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 6,552 -18,160 -73.49 234 -66.86 0.0003
2019-02-14 2018-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 24,712 19,177 346.47 706 188.16 0.0010
2018-11-14 2018-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 5,535 -152 -2.67 245 -26.65 0.0003
2018-08-14 2018-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 5,687 -10,308 -64.45 334 -54.31 0.0004
2018-05-15 2018-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 15,995 15,995 731 0.0010
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 142,700 -62.56 6,788 -66.03 n/a n/a n/a
2026-02-17 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 381,100 5.77 19,985 -14.42 n/a n/a n/a
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 360,300 169.69 23,351 259.36 n/a n/a n/a
2025-08-14 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 133,600 159.92 6,498 271.53 n/a n/a n/a
2025-05-15 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 51,400 -31.38 1,749 -40.67 n/a n/a n/a
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 74,900 26.31 2,948 5.85 n/a n/a n/a
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 59,300 -10.96 2,786 -22.57 n/a n/a n/a
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 66,600 -69.52 3,597 -75.85 n/a n/a n/a
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 218,500 35.80 14,893 47.86 n/a n/a n/a
2024-02-14 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 160,900 73.95 10,072 139.92 n/a n/a n/a
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 92,500 0.00 4,199 -19.14 n/a n/a n/a
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 92,500 -16.29 5,193 3.90 n/a n/a n/a
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 110,500 -25.54 4,998 -17.16 n/a n/a n/a
2023-02-14 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 148,400 28.04 6,032 -20.36 n/a n/a n/a
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 115,900 0.00 7,574 7.54 n/a n/a n/a
2022-08-15 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 115,900 70.69 7,043 65.25 n/a n/a n/a
2022-05-16 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 67,900 -2.86 4,262 -19.54 n/a n/a n/a
2022-02-14 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 69,900 39.80 5,297 -5.36 n/a n/a n/a
2021-11-15 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 50,000 25.00 5,597 -13.57 n/a n/a n/a
2021-08-16 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 40,000 300.00 6,476 431.26 n/a n/a n/a
2021-05-17 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 10,000 -50.00 1,219 -60.19 n/a n/a n/a
2021-02-16 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 20,000 100.00 3,062 266.27 n/a n/a n/a
2020-11-16 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 10,000 0.00 836 13.74 n/a n/a n/a
2020-08-14 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Call 10,000 0.00 735 73.35 n/a n/a n/a
2020-05-15 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 10,000 0.00 424 -30.38 n/a n/a n/a
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Call 10,000 609 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-17 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 30,200 -56.98 1,584 -65.20 n/a n/a n/a
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 70,200 4,550 n/a n/a n/a
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 35,500 208.70 1,668 168.44 n/a n/a n/a
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 11,500 -12.21 621 -30.38 n/a n/a n/a
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 13,100 -84.82 893 -83.49 n/a n/a n/a
2024-02-14 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 86,300 763.00 5,402 1,092.49 n/a n/a n/a
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 10,000 0.00 454 -19.25 n/a n/a n/a
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 10,000 -66.67 561 -58.63 n/a n/a n/a
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 30,000 -70.00 1,357 -66.64 n/a n/a n/a
2023-02-14 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 100,000 66.67 4,065 3.67 n/a n/a n/a
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 60,000 -33.33 3,921 -28.30 n/a n/a n/a
2022-08-15 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 90,000 -30.77 5,469 -32.98 n/a n/a n/a
2022-05-16 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 130,000 85.71 8,160 53.82 n/a n/a n/a
2022-02-14 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 70,000 400.00 5,305 238.54 n/a n/a n/a
2021-11-15 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 14,000 -78.12 1,567 -84.88 n/a n/a n/a
2021-08-16 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 64,000 -49.00 10,361 -32.25 n/a n/a n/a
2021-05-17 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 125,500 15,292 n/a n/a n/a
2021-02-16 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 0 -100.00 0 -100.00 n/a n/a n/a
2020-11-16 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 20,000 0.00 1,673 13.81 n/a n/a n/a
2020-08-14 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT Put 20,000 1,470 n/a n/a n/a
2019-05-15 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 0 -100.00 0 -100.00 n/a n/a n/a
2019-02-14 2018-12-31 13F CRISPR THERAPEUTICS NAMEN AKT Put 30,000 857 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.